Molecular mechanisms of drug metabolism in the critically ill

British Journal of Anaesthesia

Volumn 77, Issue 1, 1996, Pages 32-49

  Park, G R ^a  

^a ADDENBROOKE S HOSPITAL   (United Kingdom)

Author keywords

Analgesics opioid; Enzymes, cytochrome P450; Metabolism, drug; Structure, molecular

Indexed keywords

ALFENTANIL; AMITRIPTYLINE; BUPIVACAINE; CARBAMAZEPINE; CHLORAMPHENICOL; CIMETIDINE; CODEINE; CYCLOPHOSPHAMIDE; CYCLOSPORIN; CYTOCHROME P450; DANTROLENE; DEBRISOQUINE; DEXAMETHASONE; DIAZEPAM; DICLOFENAC; DIGOXIN; DRUG METABOLIZING ENZYME; ERYTHROMYCIN; HEXOBARBITAL; HYDROCORTISONE; MEFENAMIC ACID; MIDAZOLAM; MORPHINE; NORTRIPTYLINE; PARACETAMOL; PARACETAMOL DERIVATIVE; PROPOFOL; SUXAMETHONIUM; UNINDEXED DRUG; VALPROIC ACID;

AGE; CRITICAL ILLNESS; DIET; DRUG CLEARANCE; DRUG METABOLISM; DRUG PROTEIN BINDING; DRUG TRANSPORT; ENDOCRINE DISEASE; ENZYME ACTIVITY; ENZYME DEGRADATION; ENZYME INDUCTION; ENZYME INHIBITION; ENZYME POLYMORPHISM; GENETIC VARIABILITY; HUMAN; HYPOXIA; INFLAMMATION; KIDNEY FAILURE; LIVER METABOLISM; LIVER TOXICITY; PRIORITY JOURNAL; REVIEW; SEX DIFFERENCE; STRESS;

EID: 0029957068     PISSN: 00070912     EISSN: None     Source Type: Journal    
DOI: 10.1093/bja/77.1.32     Document Type: Article

References (160)

1. Abdel-Razzak Z, Loyer P, Fautrel A, Gautier J, Corcos L, Turlin B, Beaune P, Guillouzo A. Cytokines down-regulate expression of major cytochrome P-450 enzymes in adult human hepatocytes in primary culture. Molecular Pharmacology 1993; 44: 707-715.
2. Anders MW. Metabolism of drugs by the kidneys. Kidney International 1980; 18: 636-647.
3. Andreasen F. Protein binding of drugs in plasma from patients with acute renal failure. Acta Pharmacologica et Toxicologica 1973; 32: 417-429.
4. Andreasen F, Jakobsen P. Determination of frusemide in blood plasma and its binding to proteins in normal plasma and plasma from patients with acute renal failure. Acta Pharmacologica et Toxicologica 1974; 32; 417-429.
5. Angus P, Morgan D, Smallwood R. Hypoxia and hepatic drug metabolism-clinical implications. Alimentary Pharmacology Therapy 1990; 4: 213-225.
6. Armstrong SG, Renton KW. Mechanism of hepatic cytochrome P450 modulation during Listeria monocytogenes infection in mice. Molecular Pharmacology 1993; 43: 542-547.
7. Bachmann K, Shapiro R, Mackiewivcz J. Influence of renal dysfunction on warfarin plasma protein binding. Journal of Clinical Pharmacology 1976; 16: 168-172.
8. Baker MT, Chadam MV, Ronnenberg WC. Inhibitory effects of propofol on cytochrome P450 activities in rat hepatic microsomes. Anesthesia and Analgesia 1993; 76: 817-821.
9. Barry M, Feely J. Enzyme induction and inhibition. Pharmacology and Therapeutics 1990; 48: 71-94.
10. Bauer TM, Ritz R, Haberthur C, Ha HR, Hunkeler W, Sleight AJ, Scollo-Lavizzari G, Haefeli WE. Prolonged sedation due to accumulation of conjugated metabolites of midazolam. Lancet 1995; 364: 145-147.
11. Bayliss MK, Bell JA, Wilson K, Park GR. 7-Ethoxycoumarin O-deethylase kinetics in isolated rat, dog and human hepatocyte suspension. Xenobiotica 1994; 24: 231-241.
12. Bechtel YC, Joanne C, Grandmottet M, Betchel PR. The influence of insulin-dependent diabetes on the metabolism of caffeine and the expression of the debrisouin oxidation phenotype. Clinical Pharmacology and Therapeutics 1988; 44: 408-417.
13. Beck F, Whitehouse M. Impaired drug metabolism in rats associated with acute inflammation: A possible assay for anti-injury agents. Proceedings of the Society for Experimental Biology and Medicine 1974; 145: 135-140.
14. Becker GL. Effects of nonvolatile agents on oxygen demand and energy status in isolated hepatocytes. Anesthesia and Analgesia 1988; 67: 923-928.
15. Becker GL, Miletich DJ, Albrecht RF. Halogenated anesthetics increase oxygen consumption in isolated hepatocytes from phenobarbital-treated rats. Anesthesiology 1987; 67: 185-190.
16. Belpaire FM, Bogaert MG, Mussche MM. Influence of renal failure on the protein binding of drugs in animals and man. European Journal of Clinical Pharmacology 1977; 11: 27-32.
17. Bianchetti G, Graziani G, Branicaccio D. Pharmacokinetics and effects of propanolol in terminal uraemic patients and in patients undergoing regular dialysis treatment. Clinical Pharmacokinetics 1976; 1: 373-384.
18. Birnbaum J, Kahan FM, Kropp H. Carbapenems, a new class of beta lactam antibiotics. Discovery and development of imipenem/cilastatin. American Journal of Medicine 1985; 78: 3-21.
19. Bodenham A, Park GR. Plasma concentrations of bupivacaine after intercostal nerve block in patients after orthotopic liver transplantation. British Journal of Anaesthesia 1990; 64: 436-441.
20. Bodenham A, Quinn K, Park GR. Extra-hepatic metabolism of morphine. British Journal of Anaesthesia 1989; 63: 380-384.
21. Bone RC, Balk RA, Cerra FB, Fein AM, Knaus WA, Schein RMH, Sibbald WJ. Definitions for sepsis and organ failure and guidelines for the use on innovative therapies in sepsis. Chest 1992; 101: 1644-1655.
22. Buckley MM, Brogden RN, Barradell LB, Goa KL. Imipenem/cilastatin. Drugs 1992; 44: 408-444.
23. Burgess P, Hall RI, Bateman DN, Johnston IDA. The effect of total parenteral nutrition on hepatic drug oxidation. Journal of Parenteral and Enterai Nutrition 1987; 11: 540-543.
24. Carrupt PA, Testa B, Bechalany A, El Tayar N, Descas P, Perrissoud D. Morphine 6-glucuronide and morphine 3-glucuronide as molecular chameleons with unexpected lipophilicity. Journal of Medicinal Chemistry 1991; 34: 1272-1275.
25. Cassidy KM, Houston JB. In vivo capacity of hepatic and extrahepatic enzymes to conjugate phenol. Drug Metabolism and Disposition 1984; 12: 619-624.
26. Cassidy MK, Houston JB. In vivo assessment of extrahepatic conjugative metabolism in first pass effects using the model compound phenol. Journal of Pharmacy and Pharmacology 1980; 32: 57-59.
27. Chang KC, Laner BA, Bell JD, Chai H. Altered theophylline pharmacokinetics during acute respiratory viral illness. Lancet 1978; 1: 1132-1133.
28. Chen TL, Ueng TH, Chen SH, Lee PH, Fan SZ, and Liu CC. Human cytochrome P450 mono-oxygenase system is suppressed by propofol. British Journal of Anaesthesia 1995; 74: 558-562.
29. Cholerton S, Daly AK, Idle JR. The role of individual human cytochromes P450 in drug metabolism and clinical response. TIPPS 1992; 13: 434-439.
30. Choonara IA, McKay P, Hain R, Rane A. Morphine metabolism in children. British Journal of Clinical Pharmacology 1989; 28: 599-604.
31. Craig PI, Mehta I, Murray M, McDonald D, Astrom A, van der Meide PH, Farrell G. Interferon down regulates the male-specific cytochrome P450IIIA2 in rat liver. Molecular Pharmacology 1990; 38: 313-318.
32. Craig PI, Williams SJ, Cantrill E, Farrell GC. Rat but not human interferons suppress hepatic oxidative drug metabolism in rats. Gastroenterology 1989; 97: 999-1004.
33. Craig RK. Methods in molecular medicine. 2nd ed. London: BMJ, 1993: 8-16.
34. de Waziers I, Garlatti M, Bouget J, Beaune PH, and Barouki R. Insulin down-regulates cytochrome P450 2B and 2E at the pretranscriptional level in the rat hepatome cell line. Molecular Pharmacology 1995; 47: 474-479.
35. Du Souich P, Corteau H, Kobusch AB, Dalkara S, Ong H. Effect of hypoxia on the cytochrome P450 and theophylline metabolism. European Journal of Pharmacology 1990; 183: 2122-2123.
36. Duthie DR, Muir KT, Baddoo HHK, Doyle AR, Stevens JJWM, Kirkham AJT, Gupta SK, Archer S, Navapurkar VU, Park GR. Remifentanil is not metabolised by the lung. Anesthesiology 1995; 83: A324.
37. Egawa K, Yoshida M, Kasai N. An endotoxin-induced serum factor that depresses hepatic d-aminolevulinic acid synthetase activity and cytochrome P-450 levels in mice. Microbiology Immunology 1981; 25: 1091-1096.
38. El Azhary R, Renton K, Mannering G. Effect of interferon inducing agents (Polyriboinosinic Acid. Polyribocytidylic Acid and Tilorone) on the heme turnover of hepatic cytochrome P450. Molecular Pharmacology 1980; 17: 395-399
39. Elin R, Vesell E, Wolff S. Effects of etiocholanolone induced fever on plasma antipyrine half lives and the metabolic clearance. Clinical Pharmacology and Therapeutics 1975; 17:447-157.
40. Elliott SL, Morgan DJ, Angus PW, Ghabrial H, Smallwood RA. The effect of hypoxia and acidosis on propranolol clearance in the isolated perfused rat liver preparation. Biochemical Pharmacology 1993; 45: 763-765.
41. Elliott SL, Morgan DJ, Angus PW, Ghabrial H, Watson RGP, Smallwood RA. The effect of hypoxia on propranolol clearance during anterograde and retrograde flow in the isolated perfused rat liver preparation. Biochemical Pharmacology 1993; 45: 573-578.
42. Elston A, Bayliss MK, Park GR. Effect of renal failure on drug metabolism by the liver. British Journal of Anaesthesia 1993; 71: 282-290.
43. Farrel PC, Grib NL, Fry DL, Popovich RP, Broviac JW. Babb AL. A comparison of in vitro and in vivo solute-protein binding interactions in normal and uraemic individuals. Transactions of the American Society of Artificial Internal Organs 1972; 18: 268-276.
44. Farrell GC. Drug metabolism in extrahepatic disease. Pharmacology and Therapeutics 1987; 35: 375-404.
45. Ferrari L, Herber R, Batt AM, Siest G. Differential effects of human recombinant interleukin-1 beta and dexamethasone on hepatic drug-metabolizing enzymes in male and female rats. Biochemical Pharmacology 1993; 45: 2269-2277.
46. Foley EF, Borlase BC, Dzik WH, Bistrain BR, Benotti PN. Albumin supplementation in the critically ill. Archives of Surgery 1990; 125: 739-742.
47. Frenkel C, Schuttler J, Ihmsen H, Rommelsheim K. Pharmacokinetics and pharmacodynamics of propofol/ alfentanil infusions for sedation in ICU patients. Intensive Care Medicine 1995; 21: 981-988.
48. Gallenkamp H, Epping J, Fuchshoften-Rockel M, Heusler H, Richter E. Zytochrom P450-gehalt und arzneimittel-metabolismus der leber im shock Verh Dtsch Ges In Med 1982; 88: 1093-1096.
49. Ghantous H, Lofberg B, Tjaive H, Danielsson BRG, Dencker L. Extrahepatic sites of metabolism of halothane in the rat. Pharmacology and Toxicology 1988; 62: 135-141.
50. Ghezzi P, Saccardo B, Bianchi M. Induction of xanthine oxidase and heme oxygenase and depression of liver drug metabolism by interferon: A study with different recombinant interferons. Journal of Interferon Research 1986; 6: 251-256.
51. Ghezzi P, Saccardo B, Villa P, Rossi V, Bianchi M, Dinarrelo CA. Role of interleukin-1 in the depression of liver drug metabolism by endotoxin. Infection and Immunity 1986; 54: 837-840.
52. Gibson G, Skett P. Introduction to drug metabolism. London : Chapman and Hall, 1986.
53. Gibson PR, Dudley FJ. Ischemic hepatitis : clinical features, diagnosis and prognosis. Australian and New Zealand Journal of Medicine 1984; 14: 822-825.
54. Gibson TP. Renal disease and drug metabolism. An overview. American Journal of Kidney Diseases 1986; 8: 7-17.
55. Golub R, Sorrento JJ, Cantu R, Nierman DM, Moideen A, Stein HD. Efficacy of albumin supplementation in the surgical intensive care unit: A prospective, randomised study. Critical Care Medicine 1994; 22: 613-619.
56. Gong QL, Hedner J, Bjorkman R, Hedner T. Morphine-3-glucuronide may functionally antagonize morphine-6-glucuronide induced antinociception and ventilatory depression in the rat. Pain 1992; 48: 249-255.
57. Graham SG, Tateishi T, Guengerich FP, Wood AJJ, Wood M. Inhalational anesthetics inhibit CYP 2E1 activity specifically. Anesthesiology 1995; 83: A342.
58. Gray P, Park GR. Plasma concentrations of dopexamine during the anhepatic period of liver transplantation. British Journal of Clinical Pharmacology 1993; 37: 92.
59. Gray P, Park GR, Cockshott ID, Douglas ED, Shuker B, Simons PJ. Propofol metabolism in man during the anhepatic and reperfusion phases of liver transplantation. Xenobiotica 1992; 22: 105-114.
60. Greenblatt DJ, Sellers EM, Shader RI. Drug deposition in old age. New England Journal of Medicine 1982; 206: 1081-1088.
61. Groneim MM, Pandya H. Plasma protein binding of thiopental in patients with impaired renal or hepatic function. Anesthesiology 1975; 42: 545-549.
62. Grootendorst AF, van Wilgenburg MGM, de Laat PHJM, van der Hoven B. Albumin abuse in intensive care medicine. Intensive Care Medicine 1988; 14: 554-557.
63. Harper KW, Collier PS, Dundee JW, Elliott P, Halliday NJ, Lowry KG. Age and nature of operation influence the pharmacokinetics of midazolam. British Journal of Anaesthesia 1985; 57: 866-871.
64. Harris H, Whittaker M. Differential inhibition of human serum cholinesterase with fluoride: Recognition of two new phenotypes. Nature 1961; 191: 496-498.
65. Haughey DB, Kraft CJ, Matzke GR, Keane WF, Halstenson CE. Protein binding of disopyramide and elevated alpha 1 acid glycoprotein concentrations in serum obtained from dialysis patients and renal transplant recipients. American Journal of Nephrology 1985; 5: 35-39.
66. Heizmann P, Von Alten R. Determination of midazolam and its a-hydroxymetabolite in plasma by gas chromatography with electron capture detection. High Resolution Chromatography 1981; 4: 266-269.
67. Hiller A, Olkkola KT, Isohanni P, Saarnivaara L. Unconsciousness associated with midazolam and erythromycin. British Journal of Anaesthesia 1990; 65: 826-828.
68. Hooper WD, Bochner F, Eadie MJ. Plasma protein binding of diphenylhydantoin : effects of sex hormones, renal and hepatic disease. Clinical Pharmacology and Therapeutics 1974; 15: 276-282.
69. Idle J. Enigmatic variations. Nature 1988; 331: 391-392.
70. Imaoka S, Fujita S, Funae Y. Age-dependent expression of cytochrome P-450s in rat liver. Biochimica et Biophysica Acta 1991; 1097: 187-192.
71. Ismail S, Kokwaro GO, Back DJ, Edwards G. Effect of malaria infection on pharmacokinetics of paracetamol in rat. Xenobiotica 1994; 24: 527-533.
72. Jacobs JR, Croughwell ND, Goodman DK, White WD, Reves JG. Effect of hypothermia and sampling site on blood esmolol concentrations. Journal of Clinical Pharmacology 1993; 33: 360-365.
73. Jacobs JR, Reves JG, Marty J, White WD, Bai SA, Smith LR. Aging increases the pharmacodynamic sensitivity to the hypnotic effects of midazolam. Anesthesia and Analgesia 1995; 80: 143-148.
74. Janicki PK, James MF, Erskine WA. Propofol inhibits enzymatic degradation of alfentanil and sufentanil by isolated liver microsomes in vitro. British Journal of Anaesthesia 1992; 68: 311-312.
75. Johansson I, Lindros KO, Erikasson H, Ingelman-Sundberg M. Transcriptional control of CYP 2E1 in the perivenous liver region and during starvation. Biochemistry Biophysical Research Communication 1990; 173: 331-338.
76. 2 concentration in hepatocytes. Journal of Biological Chemistry 1978; 253: 4874-4880.
77. Kalow W, Genest K. A method for the detection of atypical forms of human serum cholinesterase : determination of dibucaine numbers. Canadian Journal of Biochemistry 1957; 35: 339.
78. Kanazawa Y, Kitada M, Mori T. Ascorbic acid deficiency decreases specific forms of cytochrome P-450 in liver microsomes of guinea pigs. Molecular Pharmacology 1991; 39: 456-460.
79. Kappas A, Anderson KE, Conney AH, Alvares AP. Influence of dietary protein and carbohydrate on antipyrine and theophylline metabolism in man. Clinical Pharmacology and Therapeutics 1976; 20: 643-653.
80. Kelly SD, Cauldwell CB, Fisher DM, Lau M, Sharma ML, Weisiger RA. Recovery of hepatic drug extraction after hypothermic preservation. Anesthesiology 1995; 82: 251-258.
81. Kharasch ED, Hankins D, Mautz D, Thummel KE. Identification of the enzyme responsible for oxidative halothane metabolism: implications for prevention of halothane hepatitis. Lancet 1996; 347: 1367-1371.
82. Knaus WA, Draper EA, Wagner DP, Zimmerman JE. APACHE II: a severity of disease classification. Critical Care Medicine 1985; 13: 818-829.
83. Kobayashi S, Okamura N, Kamoi K, Sugita O. Bisalbumin (fast and slow type) induced by human pancreatic juice. Annals of Clinical Biochemistry 1995; 32: 63-67.
84. Kolars JC, Awni WM, Merion RM, Watkins PB. First-pass metabolism of cyclosporin by the gut. Lancet 1991; 1488-1489.
85. Kopf M, Baumann H, Freer G, Freudenberg M, Lamers M, Kishimoto T, Zinkernagel R, Bleuthmann H, Kohler G. Impaired immune and acute phase responses in interleukin-6-deficient mice. Nature 1994; 368: 339-342.
86. Krishnaswamy K, Naidu AD. Microsomal enzymes in malnutrition as determined by plasma half-life of antipyrine. British Medical Journal 1977; 1: 538-540.
87. Kronbach T, Mathys D, Umeno M, Gonzalez FJ, Meyer UA. Oxidation of midazolam and triazolam by human liver Cytochrome P450 IIIA4. Molecular Pharmacology 1989; 36 : 89-96.
88. Kurokohchi K, Yoneyama H, Matsuo Y, Nishioka M, Ichikawa Y. Effects of interleukin 1 alpha on the activities and gene expression of the cytochrome P450 IID subfamily. Biochemical Pharmacology 1992; 44: 1669-1674.
89. Lambert A, Mitchell R, Frost J, Ratcliffe JG, Robertson WR. Direct in vitro inhibition of adrenosteroidogenesis of etomidate. Lancet 1983; 2: 1085-1086
90. Lapresle C, Wal J. The binding of penicillin to albumin molecules in bisalbuminemia induced by penicillin therapy. Biochimica et Biophysica Acta 1979; 586: 106-111.
91. Ledingham IM, Watt I. Influence of sedation on mortality in critically ill multiple trauma patients. Lancet 1983; 1: 1270.
92. Leemann T. Cles pur une prediction plus rationelle des interactions medicamenteuses. Medicine et Hygiene 1993; 51: 1033-1038.
93. Mackiewicz A, Khan MA, Gorny A, Kapcinska M, Juszczyk J, Calabrese LH, Espinosa LR. Glycoforms of alpha 1-acid glycoprotein in era of human immunodeficiency virus-infected patients. Journal of Infectious Diseases 1994; 169: 1360-1363.
94. Markewitz A, Hammer C, Pfeiffer M, Zahn S, Dreschesel J, Reichenspurner H, Reihart B. Reduction of cyclosporin induced nephrotoxicity by cilastatin following clinical heart transplantation. Transplantation 1994; 57: 865-870.
95. McKusick VA, Francomano CA, Antonarakis SE. Autosomal Dominant Phenotypes. 10th ed. Baltimore and London: Johns Hopkins University Press, 1991: 39-44.
96. Mehta MU, Venkataramanan R, Burckart GJ, Ptachcinski RJ, Yang SL, Gray JA, Van Thiel DH, Starzl TE. Antipyrine kinetics in liver disease and liver transplantation. Clinical Pharmacology and Therapeutics 1986; 39: 372-377.
97. Miahin V, von Bahr C, Ingelman-Sundberg M. Chlormethiazole as a potent and selective inhibitor in vivo of CYP2E1 during food deprivation. First International Conference on Food Nutrition and Chemical Toxicity Guildford England 1991.
98. Mode A, Gustafsson J, Jansson J, Eden S, Isaksson O. Association between plasma level of growth hormone and sex differentiation of hepatic steroid metabolism in the rat. Endocrinology 1982; 111: 1692-1696.
99. Moochhala SM. Alteration of drug biotransformation by interferon and host defense mechanism. Annals Academy of Medicine 1991; 20: 13-18.
100. Moochhala S, Renton K. Effects of the interferon inducing agent, Polyrl.rC on the synthesis of hepatic cytochrome P450. Asia Pacific Journal of Pharmacology 1989; 4: 83-88.
101. Morgan ET. Suppression of constitutive cytochrome P450 gene expression in livers of rats undergoing an acute phase response to endotoxin. Molecular Pharmacology 1989; 36: 699-707.
102. Morgan ET, Norman CA. Pretranslational suppression of cytochrome P-450h (IIC11) gene expression in rat liver after administration of interferon inducers. Drug Metabolism and Disposition 1990; 18: 649-653.
103. Mouton Perry S, Whelan E, Shay S, Wood AJJ, Wood M. Effect of i.v. anaesthesia with propofol on drug distribution and metabolism in the dog. British Journal of Anaesthesia 1991; 66: 66-72.
104. Murray M. Metabolite intermediate complexation of microsomal cytochrome P450 2C11 in male rat liver by nortriptyline. Molecular Pharmacology 1992; 42: 931-938.
105. Navapurkar V, Archer S, Gupta SK, Frazer N, Muir SK, Park GR. Pharmacokinetics of remifentanil during hepatic transplantation. Anesthesiology 1995; 83: A382.
106. Nebert DW, Nelson DR, Coon MJ, Estabrook RW, Feyereisen R, Fuji-Kuriyama Y, Gonzalez FJ, Guengerich FP, Gunsalus IC, Johnson EF, Loper JC, Sato R, Waterman MR, Waxman DJ. The P450 superfamily: Update on new sequences, gene mapping, and recommended nomenclature. DNA and Cell Biology 1991; 10: 1-14.
107. Ochs HR, Rauh HW, Greenblatt DJ, Kaschell HJ. Clorazepate disposition and diazepam in renal insufficiency: serum concentrations and proteins binding of diazepam and desmethyl diazepam. Nephron 1984; 37: 100-104.
108. Odar-Cederlof I, Borga O. Kinetics of diphenylhydantoin in uremic patients : Consequences of decreased plasma protein binding. European Journal of Clinical Pharmacology 1974 ; 7: 31-37.
109. Olson GD, Bennett WM, Porter GA. Morphine and phenytoin binding to plasma proteins in renal and hepatic failure. Clinical Pharmacology and Therapeutics 1975; 17: 677-684.
110. Osborne RJ, Joel SP, Slevin ML. Morphine intoxication in renal failure: the role of morphine-6-glucuronide. British Medical Journal 1986; 292: 1548-1549
111. Ostengaard D, Jensen FS, Jensen E, Skovgaard LT, Viby-Mogensen J. Mivacurium-induced neuromuscular blockade in patients with atypical plasma cholinesterase. Acta Anaesthesiologica Scandinavica 1993; 37: 314-318.
112. Pacifici GM, Rane A. Inhibition of morphine glucuronidation by oxazepam in human fetal liver microsomes. Drug Metabolism and Disposition 1981; 9: 569-572.
113. Park GR, Larroque C, Maurel P. Serum from critically ill patients changes the metabolism of progesterone. Anaesthesia 1994; 49: 347-348.
114. Park GR, Manara AR, Dawling S. Extrahepatic metabolism of midazolam. British Journal of Clinical Pharmacology 1989; 27: 634-637.
115. Park GR, Miller E, Navapurkar V. What changes drug metabolism in critically ill patients II? Serum interferes with midazolam metabolism. Anaesthesia 1996; (in press).
116. Park GR, Navapurkar VU, Koller J. Pharmacology of sedative and analgesic agents in the critically ill. In: Park GR, Sladen RN, eds. Oxford: Blackwell Science, 1995; 2: 18-50.
117. Park GR, Pichard L, Tinel M, Larroque C, Elston A, Domerque J, Dexionne B, Maurel P. What changes drug metabolism in critically ill patients? Two preliminary studies in isolated hepatocytes. Anaesthesia 1994; 49: 188-191.
118. Peterson TC, Renton KW. The role of lymphocytes, macrophages and interferon in the depression of drug metabolism by dextran sulphate. Immunopharmacology 1986; 11: 21-28.
119. Pineau T, Daujat M, Pichard L, Giraud F, Angevain J, Bonfils C, Maurel P. Developmental expression of rabbit cytochrome P450 CYP1A1, CYP1A2 and CYP3A6 genes. Effect of weaning and rifampacin. European Journal of Biochemistry 1991; 197: 145-153.
120. Pollack GM, Browne JL, Marton J, Haberer LJ. Chronic stress impairs oxidative metabolism and hepatic excretion of model xenobiotic substrates in the rat. Drug Metabolism and Disposition 1991; 19: 130-134.
121. Rane A, Gawronska-Szklarz B, Svensson J. Natural(-)- and unnatural(+)-enantiomers of morphine : Comparative metabolism and effect of morphine and phenobarbital treatment. Journal of Pharmacology and Experimental Therapeutics 1985; 234: 761-765.
122. Rane A, Liu Z, Henderson CJ, and Wolf CR. Divergent regulation of cytochrome P450 enzymes by morphine and pethidine: a neuroendocrine mechanism? Molecular Pharmacology 1995; 47: 57-64.
123. Rane A, Villeneuve JP, Stone WJ, Nies AS, Wilkinson GR, Branch RA. Plasma binding and distribution of frusemide in nephrotic syndrome and in uraemia. Clinical Pharmacology and Therapeutics 1978; 24: 199-207.
124. Reidenberg MM. The biotransformations of drugs in renal failure. American Journal of Medicine 1977; 62: 482-485.
125. Renton KW, Mannering GJ. Depression of hepatic cytochrome P-450 hepatic monoxygenase systems with administered interferon inducing agents. Biochemistry Biophysical Research Communication 1976; 73: 343-348.
126. Reves JG, Newfield P, Smith LR. Midazolam induction time: association with serum albumin. Anesthesiology 1981; 55 : A259.
127. Rolan PE. Plasma protein binding displacement interactions-why are they still regarded as clinically important? British Journal of Clinical Pharmacology 1994; 37:125-128.
128. Schaefer CF, Biber B, Lerner MR, Jöbsis-VanderVliet FF, Fagraeus L. Rapid reduction of intestinal cytochrome a,a3 during lethal endotoxemia. Journal of Surgical Research 1991; 51: 382-391.
129. Schumucker DL. Drug deposition in the elderly: a review of the critical factors. Journal of the American Geriatrics Society 1984; 32: 144-149.
130. Serbource-Goguel N, Corbie M, Erlinger S, Durand G, Agnerey J, Feger J. Measurement of serum 1-acid glycoprotein and 1-antitrypsin desialylation in liver disease. Hepatology 1983; 3: 356-359.
131. Serbource-Goguel N, Durand G, Corbic M, Agneray J, Feger J. Alterations in relative proportions of microheterogenous forms of human 1-acid glycoprotein in liver disease. Journal of Hepatology 1986; 2: 245-252.
132. Shedlofsky SI, Swim AT, Robinson JM, Gallicchio VS, Cohen DA, McClain CJ. Interleukin-1 (IL1) depresses cytochrome P450 levels and activity in mice. Life Sciences 1987; 40: 2331-2336.
133. Shelly MP, Gory EP, Park GR. Pharmacokinetics of morphine in two children before and after liver transplantation. British Journal of Anaesthesia 1986; 58: 1218-1223.
134. Shelly MP, Dixon JS, Park GR. The pharmacokinetics of midazolam following orthotopic liver transplantation. British Journal of Clinical Pharmacology 1989; 27: 629-633.
135. Shelly MP, Park GR, Mendel L. Failure of critically ill patients to metabolise midazolam. Anaesthesia 1987; 42: 619-626.
136. Shelly MP, Quinn K, Park GR. Pharmacokinetics of morphine in patients following liver transplantation. British Journal of Anaesthesia 1989; 63: 375-379.
137. Shelly MP, Walker S, Park GR. The pharmacokinetics of alfentanil in patients following liver transplantation. Advances in the Biosciences 1989; 76: 643-646.
138. Shingu K, Eger EL, Johnson BH. Hypoxia per se can produce hepatic damage without death in rats. Anesthesia and Analgesia 1982; 61: 820-823.
139. Shobha JC, Raghuram TC, Deva Kumar A, Krishnaswamy K. Antipyrine kinetics in undernourished diabetics. European Journal of Clinical Pharmacology 1991; 41: 359-361.
140. Smith MT, Watt JA, Cramond T. Morphine-3-glucuronide a potent antagonist of morphine analgesia. Life Science 1990; 47: 579-585.
141. Soni N. Wonderful albumin? British Medical Journal 1995; 310:887-888.
142. Stevenson IH, Dutton GJ. Glucuronide synthesis in kidney and gastrointestinal tract. Biochemical Journal 1962; 82: 330-339.
143. Stockwell MA, Soni N, Riley B. Colloid solutions in the critically ill. A randomised comparison of albumin and polygeline. 1. Outcome and duration of stay in the intensive care unit. Anaesthesia 1992; 47: 3-6.
144. Stockwell MA, Soni N, Riley B. Colloid solutions in the critically ill. A randomised comparison of albumin and polygeline. 2. Serum albumin concentration and incidences of pulmonary oedema and acute renal failure. Anaesthesia 1992; 47: 7-9.
145. Sujita K, Okuno F, Tanaka Y, Hirano Y, Inamoto Y, Eto S, Arai M. Effect of interleukin 1 (IL-1) on the levels of cytochrome P-450 involving IL-1 receptor on the isolated hepatocytes of rat. Biochemical & Biophysical Research Communications 1990; 168: 1217-1222.
146. Tan CC, Lee HS, Ti TY, Lee EJ. Pharmacokinetics of intravenous vancomycin in patients with end stage renal failure. Therapeutic Drug Monitoring 1990; 12: 29-34.
147. Tarbit MH, Bayliss MK, Herriott D, Hood SR, Hutson JL, Park GR, Serabjit-Singh CJ. Applications of molecular biology and in vitro technology to drug metabolism studies : an industrial perspective. Biochemical Society Transactions 1993; 21: 1018-1023.
148. Teunissen MWE, Srivastava AK, and Breimer DD. Influence of sex and the oral contraceptive steroids on antipyrine metabolite formation. Clinical Pharmacology and Therapeutics 1982; 32: 240-246.
149. Trenholme G, Williams R, Rieckmann K, Frischer H, Carson P. Quinine disposition during malaria and during induced fever. Clinical Pharmacology and Therapeutics 1976; 19: 459-467.
150. Tsutsumi M, Lasker JM, Shimizu M, Rosman AS, Lieber CS. The intralobular distribution of ethanol-inducible P450 IIEI in rat and human liver. Hepatology 1989; 10: 437-446.
151. Vasson MP, Roch-Arveiller M, Couderc R, Baguet JC, Raichvarg D. Effects of alpha-1 acid glycoprotein on human polymorphonuclear neutrophils : influence of glycan microv heterogeneity. Clinica Chimica Acta 1994; 224: 65-71.
152. Venkataramanan R, Kalp K, Rabinovitch R, Cuellar R, Ptachcinski RJ, Teperman L, Makowka L, Burckart GJ, Van Thiel DH, Starzl TE. Conjugative drug metabolism in liver transplant patients. Transplant Proceedings 1989; 21: 2455.
153. Vickers AE, Fischer V, Connors S, Fisher RL, Baldeck J, Maurer G, Brendel K. Cyclosporin A metabolism in human liver, kidney, and intestine slices. Comparison to rat and dog slices and human cell lines. Drug Metabolism and Disposition 1992; 20: 802-809.
154. Wang GL, Semenza GL. General involvement of hypoxiainducible factor 1 in transcriptional response to hypoxia. Proceedings of the National Academy of Sciences of the USA 1993; 90: 4304-4308.
155. Weitz CJ, Lowney LI, Faull KF, Feistner G. Goldstein A. Morphine and codeine from mammalian brain. Neurobiology 1986; 83: 9784-9788.
156. Whittaker M, Britten JJ, Wicks RJ. Inhibition of the plasma cholinesterase variants by propranolol. British Journal of Anaesthesia 1981; 53: 511-516.
157. Woo J, Chan HS, Or KH, Arumanayagam M. Effects of age and disease on two drug binding proteins: albumin and alpha-1-acid glycoprotein. Clinical Biochemistry 1994; 27: 289-292.
158. Yang CS, Brady JF, Hong J. Dietary effects on cytochrome P450, xenobiotic metabolism and toxicity. FASEB Journal 1992; 6: 737-744.
159. Yun Y, Casazza JP, Sohn DH, Veech RL, Song BJ. Pretranslational activation of cytochrome P450IIE during ketosis induced by a high fat diet. Molecular Pharmacology 1992; 41: 474-479.
160. Zenser TV, Rapp NS, Mattammal MD. Renal cortical drug and xenobiotic metabolism following urinary tract obstruc-tion. Kidney International 1984; 25: 747-752.